<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To determine whether pranlukast, a <z:chebi fb="0" ids="23511,32460">cysteinyl</z:chebi> <z:chebi fb="0" ids="25029">leukotriene</z:chebi> receptor-1 antagonist, exerts an anti-inflammatory effect on focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in mice </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in mice was induced by permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="2" pm="."><plain>In addition to neurological deficits, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, degenerated neurons and endogenous IgG exudation, we detected accumulation of neutrophils and macrophage/microglia in the ischemic brain tissue 72 h after MCAO </plain></SENT>
<SENT sid="3" pm="."><plain>Pranlukast was ip injected 30 min before and after MCAO </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Pranlukast significantly attenuated neurological deficits, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, <z:mp ids='MP_0003224'>neuron degeneration</z:mp> and IgG exudation </plain></SENT>
<SENT sid="5" pm="."><plain>Importantly, pranlukast (0.01 and 0.1 mg/kg) inhibited myeloperoxidase-positive neutrophil, but not CD11b-positive macrophage/microglial accumulation in the ischemic cortical tissue </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Pranlukast exerts an anti-inflammatory effect on focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in the <z:hpo ids='HP_0011011'>subacute</z:hpo> phase that is limited to neutrophil recruitment through the disrupted blood-brain barrier </plain></SENT>
</text></document>